NPSP Share Price

Open 45.87 Change Price %
High 45.88 1 Day 0.12 0.26
Low 45.85 1 Week 0.00 0.00
Close 45.97 1 Month 0.00 0.00
Volume 4541971 1 Year 0.00 0.00
52 Week High 12.53
52 Week Low 0.00
NPSP Important Levels
Resistance 2 46.00
Resistance 1 45.99
Pivot 45.90
Support 1 45.95
Support 2 45.94
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
WRES 0.09 0.00%
SIRI 4.41 1.85%
QQQ 116.87 0.23%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
ECTE 0.14 40.00%
BNSO 3.57 31.25%
FRAN 20.01 28.76%
FRAN 20.01 28.76%
FRAN 20.01 28.76%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
CRDS 5.45 25.87%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
IMRS 0.02 -33.33%
More..

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP)

NPSP Technical Analysis 5
As on 20th Feb 2015 NPSP Share Price closed @ 45.97 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 31.61 & Strong Buy for SHORT-TERM with Stoploss of 40.70 we also expect STOCK to react on Following IMPORTANT LEVELS.
NPSP Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
NPSP Other Details
Segment EQ
Market Capital 798695104.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.npsp.com
NPSP Address
NPSP
550 Hills Drive
Bedminster, NJ 07921
United States
Phone: 908-450-5300
Fax: 908-450-5351
Interactive Technical Analysis Chart NPS Pharmaceuticals, Inc. ( NPSP NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on NPS Pharmaceuticals, Inc.
NPSP Business Profile
NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The Company�s primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved by the United States Food and Drug Administration (FDA) during the year ended December 31, 2012, for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. Natpara is the recombinant full-length human parathyroid hormone (rhPTH (1-84)), which is developing as a hormone replacement therapy for hypoparathyroidism, a rare hormone deficiency disorder, in which patients are physiologically unable to regulate the levels of calcium and phosphates in their blood due to insufficient levels of endogenous parathyroid hormone (PTH).